Johnson & Johnson

JNJ

Market cap $599B

SOXX dips into a bear market

Johnson & Johnson JNJ announced robust second-quarter 2026 results on July 15, beating estimates for both earnings and sales. While earnings rose 4.7%, sales rose 6.6% from the year-ago period.

The healthcare giant is on track to report full-year revenue of more than $100 billion. The company raised guidance for annual revenue and earnings per share.

The three biggest US pharma names by market cap trade at very different setups right now: Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) at $247.02 screens as the most compelling on fundamentals, Eli Lilly (NYSE:LLY) at $1,156.63 looks fully valued, and AbbVie (NYSE:ABBV) at $244.11 appears stretched relative to its growth outlook.

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a stock built to be owned for decades, not traded, because its combination of an AAA-tier balance sheet, a 64-consecutive year dividend growth streak and a diversified healthcare franchise across pharmaceuticals and medical devices is engineered to compound quietly through every market cycle.

July tests investor conviction. From the 2011 debt-ceiling standoff to the 2022 inflation shock, summer volatility has separated durable businesses from cyclical hopefuls.

On Thursday, July 16, during the broadcast of Mad Money , Jim Cramer pushed back on the market's punishment of several blue-chip companies that just posted strong quarters.

JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.

Johnson & Johnson posted strong Q2 earnings. Sales of its NMDA receptor antagonist, called Spravato, for the treatment of depression, rose 41.1% year-on-year to $584 million in Q2. Also, J&J raised its 2026 adjusted diluted EPS guidance from $11.45-$11.65 to $11.6-$11.75.

Johnson & Johnson (NYSE:JNJ) shares rose in early trading on Thursday, after the company reported upbeat second-quarter results.